BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (1995) 68, 636-645
© 1995 British Institute of Radiology
doi:
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Attard, A. R.
Right arrow Articles by Bradwell, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Attard, A. R.
Right arrow Articles by Bradwell, A. R.

The British Journal of Radiology, Vol 68, Issue 810 636-645, Copyright © 1995 by British Institute of Radiology

ARTICLES

Model based calculation for effective cancer radioimmunotherapy

AR Attard, MJ Chappell and AR Bradwell
Department of Immunology, University of Birmingham Medical School, UK.

The major problem of tumour radioimmunotherapy remains the low tumour antibody uptake and this leads to inadequate tumour irradiation. The antibody characteristics which influence uptake have been identified and quantified previously using a non-linear compartmental model that simulates antibody distribution to tumour and body after intravenous injection. The model has now been extended, in combination with MIRD dosimetry tables, to calculate the integral tumour/body radiation dose for a range of antibody masses (1, 10 and 50 mg), sizes (binding site fragments and whole molecules) and affinities (K = 10(9)-10(13) mol-1). Antibody requirements for delivering 60 Gy to the tumour over 11.6 days were calculated for 131I and 90Y-labelled antibodies and included the effect of widely varying dose rates. The model predicted that intact antibodies of high affinity (10(11)-10(13) mol-1) produced effective tumour radiation doses with acceptable whole body radiation levels. By contrast, antibody fragments gave higher body radiation levels and required larger injected activity because of renal excretion. The model predicted higher therapeutic indices for 90Y-labelled antibody compared with 131I.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. M. Cardillo, Z. Ying, and D. V. Gold
Therapeutic Advantage of 90Yttrium- versus131Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer
Clin. Cancer Res., October 1, 2001; 7(10): 3186 - 3192.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 1995 by the British Institute of Radiology.